We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Identifies Septic Shock Risk Biomarkers

By LabMedica International staff writers
Posted on 10 Apr 2014
A multibiomarker-based approach has been developed to estimate mortality risk in adults with septic shock and tested on blood samples from critically ill patients.

Septic shock is a severe systemic infection and major cause of death for the old and young alike, but testing new drug regimens to stop the infection is confounded because clinical trials include patients who are either too sick to be saved by experimental therapies or not sick enough to warrant the treatments. More...


An international team led by scientists at the Cincinnati Children's Hospital Medical Center (OH, USA) studied 882 adults in intensive care units in medical centers located in the USA, Finland and Canada. The study included three different groups of patients to develop, test and retest the tool. This helps to make sure it works in different patient mixes, often a limiting factor in large clinical trials. The team selected 12 candidate biomarkers from 117 gene probes previously shown to have predictive strength for poor outcomes in microarray-based studies involving children with septic shock.

The plasma concentrations of the candidate biomarkers were measured using a multiplex magnetic bead platform, the MILLIPLEX MAP (EMD Millipore Corporation; Billerica, MA, USA) and a Luminex 100/200 multiplex analyzer system (Luminex Corporation; Austin, TX, USA). Maximum accuracy was achieved with five of the 12 candidate stratification biomarkers: C-C chemokine ligand 3 (CCL3), heat shock protein 70 kDa 1B (HSPA1), interleukin-8 (IL8), granzyme B (GZMB), and C-C chemokine ligand 4 (CCL4). Serum lactate concentration at study entry, age, and presence of chronic disease further improved predictive accuracy.

The data was then used in a mathematical model to combine the information into a single tool that separates high- and low-risk patients. The investigators found that the tool accurately determined that patients who tested positive had less than a 50% chance of surviving, but patients who tested negative had more than a 90% chance of surviving. More detailed analyses allowed the authors to identify patients with a more than a 98% chance of surviving, and those with more than 75% chance of dying.

Hector R. Wong, MD, a lead investigator and director of Critical Care Medicine said, “Substantial resources are invested in trying to find new treatments for septic shock, but the vast majority of them fail when they get to clinical trials. There are many reasons for this, but a consistent one is that the baseline mortality risk varies widely in septic shock patients, which muddies the water.” The study was published in the April 2014 issue of the journal Critical Care Medicine.

Related Links:

Cincinnati Children's Hospital Medical Center 
EMD Millipore Corporation
Luminex Corporation



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.